Analysis of the Impact of AnaptysBio Insider Trading on Investment Value

---

AnaptysBio, Inc. (NASDAQ: ANAB) has recently seen a concentrated share sale by multiple executives. Chief Legal Officer Eric Loumeau sold approximately

worth of shares between December 16-18, 2025 [0]. This insider trading activity has raised investor concerns about the company’s valuation. Combining the company’s fundamentals, financial status, and technical analysis, this report will comprehensively assess the potential impact of this insider sale on investment value.

---

According to SEC Form 4 filings, three core executives of AnaptysBio conducted share sales in mid-December 2025 [1][2]:

Transaction Date	Number of Shares	Average Transaction Price	Transaction Amount
2025-12-16	8,305	$44.68	$371,028
2025-12-16	4,195	$45.24	$189,769
2025-12-17	10,000	$46.00	$460,000
2025-12-18	141	$46.99	$6,626
Total	22,641	-	$1,027,423

After the sale, Mr. Loumeau directly holds

, representing a significant decrease of approximately 52.78% in his shareholding ratio [3].

• Transaction Date: December 16, 2025
• Shares Sold: 15,725
• Average Transaction Price: $44.85
• Proceeds: $705,266
• Remaining Shares Held: 9,401 (a 62.58% decrease) [4]

• Transaction Date: December 22, 2025
• Shares Sold: 1,500
• Average Transaction Price: $50.00
• Proceeds: $75,000
• Remaining Shares Held: 26,967 [5]

All transactions were executed pursuant to a pre-arranged [1][2].

Key features of the 10b5-1 plan:

• The plan was established by Mr. Loumeau on April 11, 2025
• Complies with SEC regulations, pre-established when no material non-public information was held
• Has a fixed execution schedule and price conditions
• Designed to avoid suspicion of insider trading

This indicates that this share sale is a

, rather than an impulsive decision based on short-term information advantages.

---

From a traditional investment perspective, insider share sales are typically viewed as a bearish signal:

Negative Factors	Details
Concentrated Share Sale	Three executives sold shares within a similar time window, with total proceeds of approximately $1.8 million
Proceeds at High Price	Transactions occurred when the stock price was near its 52-week high (reached $52.00 on December 27)
Sharp Reduction in Shareholdings	Loumeau only holds 8,947 shares after the sale, while Mulroy only holds 9,401 shares
Industry Sensitivity	Biotechnology companies are highly sensitive to changes in executive confidence

However, in-depth analysis shows that this transaction may not reflect negative views from management regarding the company:

Bullish/Neutral Factors	Details
Pre-Arranged Plan	The 10b5-1 plan indicates the transaction is part of long-term planning, not an impulsive decision
Company Share Repurchase	In November 2025, the company announced a $100 million share repurchase plan, demonstrating management’s confidence in the company’s value [6]
Financial Health	Current ratio as high as 8.68, cash reserves expected to reach $300M
Earnings Beat Expectations	FY2025 Q3 EPS was $0.52, exceeding expectations by 149% [0]
Analyst Bullish Sentiment	65% of analysts have given a Buy rating, with a consensus target price of $55.50 [0]
Small Proportion of Market Value	Total proceeds of approximately $1.8 million, accounting for only 1.5% of the company’s market capitalization ($1.22B)

---

Based on the latest financial data [0]:

Financial Indicator	Value	Assessment
Market Capitalization	$1.22B	Mid-sized biotechnology company
Current Ratio	8.68	Extremely healthy
Current Assets/Short-term Liabilities	8.68x	Low financial risk
P/E	N/A	Not applicable (in R&D phase, not yet profitable)

Period	Revenue	EPS	Remarks
Q3 FY2025	$76.32M	$0.52	Significantly exceeded expectations
Q2 FY2025	$22.26M	-$1.34	Incurred a loss
Q1 FY2025	$27.77M	-$1.28	Incurred a loss
Q4 FY2024	$43.11M	-$0.72	Incurred a loss

The company expects to receive a from GSK in Q4 2025, conditional on Jemperli reaching $1 billion in global net sales [6].

Indicator	Value
Consensus Target Price	$55.50
Potential Upside	+26.4%
Target Price Range	$36.00 - $140.00
Proportion of Buy Ratings	65%
Proportion of Hold Ratings	35%

Recent Analyst Actions (November-December 2025):

• Barclays: Maintained Overweight rating [0]
• Stifel: Maintained Buy rating [0]
• HC Wainwright: Maintained Buy rating [0]
• Wedbush: Maintained Outperform rating [0]

---

• Current Stock Price: $43.91
• 52-Week High: $52.47
• 52-Week Low: $12.21
• Decline from High: -16.31%
• Increase from Low: +259.6%

• 2025 Increase: +186.99%
• Year-to-Date (as of January 2026): -2.31%
• 3-Month Increase: +45.16%
• 6-Month Increase: +87.25%

Indicator	Value	Interpretation
MA20 (20-day Moving Average)	$46.85	Stock price is below the short-term moving average (-6.28%)
MA50 (50-day Moving Average)	$41.46	Stock price is above the medium-term moving average (+5.91%)
RSI (14-day)	44.83	Neutral zone, no overbought or oversold conditions
MACD	1.28	Below the signal line, bearish
20-day Annualized Volatility	45.62%	High volatility

As seen from the technical chart:

• During the insider sale period (December 16-18), the stock price was in a short-term correction phase
• Trading volume remained at normal levels, with no abnormal volume spikes
• The stock price began to pull back after hitting the 52-week high of $52.00 on December 29

---

Factor	Weight	Direction	Explanation
Execution of 10b5-1 Plan	High	Neutral	Pre-arranged transactions reduce suspicion of insider trading
Proportion of Proceeds to Market Value	Low	Neutral	Accounts for only 1.5% of market capitalization
Concentrated Share Sale by Executives	Medium	Bearish	May reflect concerns about valuation
Company Share Repurchase Plan	High	Bullish	Management supports the stock price through actions
Financial Health Status	High	Bullish	Adequate cash reserves, healthy current ratio
Performance	Medium	Bullish	Q3 results exceeded expectations
Analyst Expectations	Medium	Bullish	26% upside potential from target price
Industry Risk	High	Bearish	Biotechnology R&D risks

This insider sale is to have a significant negative impact on AnaptysBio’s long-term investment value.

1. Compliance of Trading Plan:
   All transactions are pre-arranged 10b5-1 plan transactions, not impulsive decisions, indicating that management’s share sale is not based on negative information.
2. Endorsement via Company Share Repurchase:
   Management sold shares after the company announced the $100M repurchase plan, which does not directly conflict with the company’s repurchase actions.
3. Sound Fundamentals:
   • Adequate cash reserves (expected to reach $300M)
   • Extremely high current ratio (8.68x)
   • Q3 results exceeded expectations
   • Potential $75M milestone revenue
4. Analyst Confidence:
   65% Buy ratings and a consensus target price of $55.50 show that professional institutions remain optimistic about the company’s prospects.
5. Small-Scale Transaction:
   Total proceeds of approximately $1.8 million, accounting for an extremely low proportion (1.5%) of the $1.22B market capitalization.

Investors still need to pay attention to the following risks:

1. Short Selling Pressure:
   More than 30% of floating shares are shorted [7], indicating significant market divergence
2. High Volatility:
   Annualized volatility of 45.62%, with sharp stock price fluctuations
3. Biotechnology Risks:
   Uncertainty regarding clinical trial results
4. Valuation Pressure:
   Currently down 16% from the 52-week high; support levels need to be monitored

---

Investor Type	Recommendation
Existing Shareholders	Hold and monitor; no need to panic sell due to the insider sale
Potential Investors	May consider accumulating shares on dips in the $40-42 range
Risk-Tolerant Investors	Monitor the upcoming Q4 earnings report (February 26, 2026)

1. Q4 Earnings Report on February 26, 2026:
   Monitor EPS expectations ($0.89) and revenue guidance
2. GSK Milestone Payment:
   Confirmation timing of the $75M milestone
3. Subsequent Insider Trading:
   Monitor whether more executives sell shares
4. Institutional Holding Changes:
   Monitor changes in positions by large institutional investors

---

The share sale by AnaptysBio’s executive team may trigger investor concerns in the short term, but from a multi-dimensional analysis, the impact of this transaction on the company’s long-term investment value is limited. The use of a pre-arranged 10b5-1 trading plan, compliant transaction timing, and the company’s own share repurchase plan all indicate that this is more a reflection of the executives’ personal financial planning rather than a negation of the company’s prospects.

Considering the company’s healthy financial status, earnings that exceeded expectations, and positive analyst ratings, investors should view this insider sale as a

, rather than a significant sell signal. However, given the high-risk nature of the biotechnology industry and the stock’s high volatility, it is recommended that investors make prudent decisions based on their own risk tolerance.

---

[0] Jinling API - AnaptysBio Company Profile and Market Data

[1] SEC Form 4 - Eric Loumeau Transaction Disclosure (https://www.sec.gov/Archives/edgar/data/1239648/000123964825000005/0001239648-25-000005.txt)

[2] TradingView - AnaptysBio Executives Sell Shares (https://www.tradingview.com/news/tradingview:5f854cdf0bfa5:0-anaptysbio-executives-sell-shares/)

[3] WhaleWisdom - Form 4 Insider Filing Concerning ANAB (https://whalewisdom.com/filing/loumeau-eric-j-4-2025-12-18-161404-0500-anab)

[4] InsiderTrades - Dennis Mulroy Sells 15,725 Shares (https://www.insidertrades.com/alerts/nasdaq-anab-insider-buying-and-selling-2025-12-19/)

[5] InsiderTrades - Paul Lizzul Sells 1,500 Shares (https://www.insidertrades.com/alerts/nasdaq-anab-insider-buying-and-selling-2025-12-24/)

[6] AnaptysBio IR - $100 Million Stock Repurchase Plan (https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-100-million-stock-repurchase-plan)

[7] Barchart - This Biotech Stock Has More Than Tripled in 2025 (https://www.barchart.com/story/news/36717167/this-biotech-stock-has-more-than-tripled-in-2025-but-red-flags-are-waving)